TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Glycemic Index, Body Weight and Health
Brief Summary: The purpose of this study is to investigate the effect of a diet with either high or low glycemic index (GI) on ad libitum (free) food intake, body weight, fat mass and fat-free mass, risk markers for diabetes and cardiovascular diseases, energy expenditure and substrate oxidation after 10 weeks´ intake in slightly overweight subjects.


Options:
A: Inclusion Criteria:

* 18-65 years old
* overweight or obese
* prediabetes with elevated glucose value

Exclusion Criteria:

* recent cardiovascular event
* use of corticosteroids
* concurrent participation in a structured weight loss program
* pregnant or lactating
B: Inclusion Criteria:

* Men and postmenopausal women with type 2 diabetes treated with diet plus oral hypoglycemic agents (Sulfonylureas, Biguanides, Thiazolidinediones , and new secretagogues (Repaglinide)) at a stable dose for at least 3 months prior to starting the study
* HbA1c between 6.5 and 8.0% at recruitment
* living within a 40 km radius of St. Michael's Hospital
* Diabetes diagnosed \> 6 months prior to randomization

Exclusion Criteria:

* diabetic complications: clinically significant gastroparesis, retinopathy, nephropathy, neuropathy, hepatic disease, or CHD (current clinically significant CHD e.g. unstable angina)
* taking insulin or acarbose
* smoking or significant alcohol intake (\> 1 drink/day)
* serum triglycerides \> 4.0 mmol/L
C: Inclusion Criteria:

* healthy, slightly overweight (body mass index, BMI = 25-30 kg/m2) women, premenopausal, non-alcoholic (\< 14 units alcohol/w)

Exclusion Criteria:

* smoking, elite athletes, food allergies, pregnant, lactating, on medication, blood donation 3 months before, during and 3 months after the completion of the study
D: Inclusion Criteria:

* Families with healthy adults and children

Exclusion Criteria:

* Various

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Telepsychology-Service Delivery for Depressed Elderly Veterans
Brief Summary: The purpose of this study is to see whether therapy for elderly adults with major depression can be delivered effectively using videoconferencing technology ("telepsychology"), which allows a therapist and patient who are not in the same room as one another to communicate. We are interested in learning if this form of mental health service delivery is an acceptable alternative to traditional face-to-face therapy delivered with the therapist in the same room as the patient.


Options:
A: Inclusion Criteria:

- Pregnant PHQ9 Depression Score of 15 or greater Receiving prenatal care at one of the participating sites

Exclusion Criteria:

- Known diagnosis of bipolar or psychotic disorder Active substance dependence Immediate risk of self harm Immediate need for inpatient mental health treatment
B: Inclusion Criteria:

* Adults (aged ≥18 years).
* Adults with possible mild to moderately severe depression reflected by a score of between 10 and 23 (i.e. moderate to moderately severe depressive symptoms) on the Patient Health Questionnaire (PHQ-8) as has been done in previous studies looking at low mood and depressive symptoms.
* Adults living in the UK.
* Having access to the internet.
* Able to walk continuously and unaided for a minimum of 5 minutes.
* Provision of informed consent to participate.

Exclusion Criteria:

* Adults (aged \<18 years).
* Adults without possible mild to moderately severe depression reflected by a score of between 10 and 23 (i.e. moderate to moderately severe depressive symptoms) on the Patient Health Questionnaire (PHQ-8) as has been done in previous studies looking at low mood and depressive symptoms.
* Adults not living in the UK.
* No access to the internet.
* Not able to walk continuously and unaided for a minimum of 5 minutes.
* Lacking capacity to give informed consent to participate.
C: Inclusion Criteria:

* depressive symptoms according to DSM-IV
* have access to a smartphone and to the Internet
* have good knowledge of the Swedish language

Exclusion Criteria:

* recent (during last 6 weeks) change in psychiatric medication
* presently in any other psychological treatment
* severe depression
* suicidal ideation
D: Inclusion Criteria:

* Participants will be older male and female veterans,
* age 60 and above,
* with diagnoses of major depressive disorder (MDD) assigned on the basis of the Structured Clinical Interview for DSM-IV (SCID; Spitzer et al., 1997).

Exclusion Criteria:

* Actively psychotic or demented persons,
* individuals with both suicidal ideation and clear intent, and
* individuals meeting criteria for substance dependence will be excluded from participation.

However, in order to maximize generalization of results, presence of other forms of psychopathology will not be a basis for exclusion. All of these structured interviews will be audiotaped in order to calculate inter-rater reliability on a randomly selected 20%. (See Human Subjects for procedures in place for suicidal participants or potential participants).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: It is increasingly recognised that rapid growth in infancy may be associated with a greater risk of cardiovascular disease later in life. This trial will investigate whether the use of infant feeding bottles with different designs influences the milk intake and growth of infants. We will compare the growth of bottle-fed infants with that of a breast-fed reference group.


Options:
A: Inclusion Criteria:

* Infants born ≤ 32 weeks gestation

Exclusion Criteria:

* Infants will be excluded if the infant has gastrointestinal, craniofacial, cardiovascular, neuromuscular, and/or genetic defects
B: Inclusion Criteria:

* Term babies born to mothers by normal vaginal delivery in the study period.

Exclusion Criteria:

1. Babies with major congenital malformation.
2. Multiple pregnancy
3. Babies requiring resuscitation beyond the initial steps
4. Babies requiring care in the neonatal intensive care unit.
5. Maternal problems requiring immediate care

   * Severe preeclampsia defined as Blood pressure more than 160/110, Proteinuria more than 3+, Oliguria less than 500 ml, Pulmonary edema, cerebral visual disturbances, Impaired liver function, Thrombocytopenia, Epigastric Pain
   * Imminent eclampsia
   * Severe bleeding
   * Mother with significant surgical or medical illness requiring separation of the baby from the mother.
6. Small for dates and large for dates babies
7. Infants of diabetic mother
8. Maternal refusal of consent.
C: Inclusion Criteria:

* healthy term infants birth weight \>2.50kg, gestational age \>37 weeks

Exclusion Criteria:

-
D: Inclusion Criteria:

* infants with between 26 and 32 weeks gestational age as determined by date of last menstruation and first trimester ultrasound or by clinical examination.

Exclusion Criteria:

* infants with medical complications, such as grades III or IV intraventricular hemorrhage or periventricular leukomalacia
* congenital diseases such as chromosomal or genetic abnormalities
* bronchopulmonary dysplasia
* necrotizing enterocolitis.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate
Brief Summary: The purpose of this study is to determine whether childhood atopic disease decrease or not after allowing allergic mothers intake of probiotic (Lactobacillus GG) in second trimester, followed by infant intake for 6 months after birth.


Options:
A: Inclusion Criteria:

* over 18 years old
* able to give informed consent

Exclusion Criteria:

* twin pregnancies, pregnancy diseases (threat of miscarriage, maternal chronic conditions)
B: Inclusion Criteria:

* Greater than 12 weeks pregnant
* between the ages of 18 and 40 years

Exclusion Criteria:

* Less than 12 weeks pregnant
C: Inclusion Criteria:

* Pregnant women with atopic disease, which was determined with atopic history, elevated total IgE \> 100 kU/l and positive specific IgE

Exclusion Criteria:

* Multiple pregnancy
D: Inclusion Criteria:

* Aged 6-10
* Attends Lake Primary School (Mwanza, Tanzania)

Exclusion Criteria:

* Allergic to milk/ milk products
* Lactose intolerant

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate
Brief Summary: The purpose of this study is to determine whether childhood atopic disease decrease or not after allowing allergic mothers intake of probiotic (Lactobacillus GG) in second trimester, followed by infant intake for 6 months after birth.


Options:
A: Inclusion Criteria:

* History of at least 3 episodes of wheezing bronchitis,
* First degree relative with history of allergic disease

Exclusion Criteria:

* Congenital malformations,
* Immunologic or oncologic systemic disorders,
* Current antibiotic therapy,
* Prior exposure to probiotics; and
* Known intolerances towards ingredients of the probiotics (LGG, microcristalline cellulose, gelatine, magnesiumstearate, titandioxide).
B: Inclusion Criteria:

* Pregnant women with atopic disease, which was determined with atopic history, elevated total IgE \> 100 kU/l and positive specific IgE

Exclusion Criteria:

* Multiple pregnancy
C: Inclusion Criteria:

1. Age between 1 year old and 18 years old,
2. AD cases fulfill the diagnostic criteria by Hannifin and Rajka.
3. Atopy as shown by at least one positive skin test (weal size ≧ 3mm) or one positive MAST (RAST) (IgE ≧ 0.7 kU/L) test to any common food or environmental allergens.

Exclusion Criteria:

1. Systematic corticosteroid, immunosuppressive therapy, or antimycotics treatment during the 4 weeks, antihistamines, and singulair during the 7 days before enrollment
2. Probiotic preparations used within 2 weeks before entering the study
3. Use of antibiotics now or other oral medications that will interfere the results
4. If they had immune deficiency disease or other major medical problems
5. If they had participated in another clinical study during the past month.
6. Subjects are undergoing desensitization therapy within 3 months prior to the screening period.
7. Subjects have participated investigational drug trial within 4 weeks before entering this study.
8. Subjects are pregnant, lactating or planning to become pregnant.
9. Subjects with any other serious diseases considered by the investigator that could interfere with the performance of SCORAD score result.
10. Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication.
D: Inclusion Criteria:

* clinical diagnosis of atopic dermatitis
* age 4 we - 18 mo

Exclusion Criteria:

* skin infection or severe infection at the time of enrollment

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Patient Decision Aid Regarding Natural Health Products for Menopausal Symptoms:a Randomized Controlled Trial
Brief Summary: The aim of this study is to assess the impact of a patient decision aid regarding natural health products for menopausal symptoms on decisional conflict, knowledge and persistence for an option of women aged 45-64 years old. We are expecting a decrease in decisional conflict and an improvement on knowledge level. We are also expecting an intention to use the decision aid in the future and to discuss with the physician or pharmacist about the use, or the intention to use natural health products.


Options:
A: Inclusion Criteria:

* dementia diagnosis
* advanced cognitive impairment
* feeding problem
* age \>= 65
* surrogate decision maker

Exclusion Criteria:

* feeding tube decision made
* hospice
* BMI \> 26
* major psychosis or developmental delay
B: Inclusion Criteria:

Women :

* between 45 and 64 years old
* reporting suffering from menopausal symptoms
* considering the use of natural health products for menopausal symptoms
* able to read, write, and understand french at a grade 8 level
* able to give an informed consent for her participation to the study

Exclusion Criteria:

* manager and/or owner of a natural health products store,a pharmacy and/or a pharmaceutical company
* person with close relationships with one or many collaborators of this study
* reporting suffering from symptoms with no precise diagnosis
C: Inclusion Criteria:

* For physician intervention inclusion criteria included; 1)primary care (general internist or family) physician in HealthPartners Medical Group. 2)Provided ongoing care to 20 or more adult patients with diabetes.
* For patients inclusion criteria included; An established diagnosis of diabetes based on either (a) two or more ICD-9 diagnosis codes for diabetes in a 12-month period of time, or (b) a filled prescription for a diabetes-specific drug within a 12-month period of time.

In addition, participating patients met all of the following criteria: (a) age less than 75 years, (b) Charlson comorbidity score of 3 or less, (c) linked to the a primary care physician who was participating in the study in two consecutive calendar years, (d) had pharmacy coverage at the time of the intervention and for the previous 12-month period, and (e) had either HBA1c \> 7% or LDL \> 130 mg/dl (or LDL \> 100 mg/dl if the patient also had CHD).

Exclusion Criteria:

* none
D: DISEASE CHARACTERISTICS:

* Believed to be at increased risk of breast cancer (risk of ≥ 1.66% over 5 years) according to electronic-based medical data

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Brief Summary: This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.


Options:
A: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I or II
* aged between 18 to 60yr
* scheduled for elective gynecological laparoscopic surgery requiring general anesthesia

Exclusion Criteria:

* pregnancy or breastfeeding
* mental retardation
* psychiatric or neurological disease
* use of antiemetics, emetogenic drugs, opioids or glucocorticosteroids within 3 days prior to surgery
* known allergy to tropisetron or dexamethasone
* nausea and/or vomiting within 24 hr prior to surgery
* implantation of a cardiac pacemaker, cardioverter, or defibrillator
* any skin problem at the acupoint stimulation area
B: Inclusion criteria:

* History of PONV and/or motion sickness.
* Have not smoked for the last 6 months.
* Having certain types of abdominal, breast or shoulder surgeries.

Exclusion criteria:

* Pregnant or breastfeeding.
* Taking certain medications.
* Have certain pre-existing medical conditions.
C: Inclusion Criteria:

* Patients who were scheduled for MVD of trigeminal nerve root
* Patients who had a physical status classification of I to III according to the American Society of Anesthesiologists, and those who had a body mass index of 18 to 35 kg/m2

Exclusion Criteria:

* Patients on long-term administration of dexamethasone or ondansetron, those with a history of allergic reactions to dexamethasone or ondansetron, those who had undergone antiemetic therapy within 24 hr before surgery, those with underlying liver or renal failure, those who were pregnant, or those who had undergone emergency surgery.
D: Inclusion Criteria:

* 18-80 yrs of age
* American Society of Anesthesiologists (ASA) physical status 1-3
* Scheduled for outpatient TEP bilateral inguinal hernia repair

Exclusion Criteria:

* Patients refusal to participate
* inability to give consent
* drug allergies to medications used in study
* pregnancy
* bleeding diathesis
* conversion to an open procedure
* any subject whose anatomy, or surgical procedure, in the opinion of the investigator might preclude the potential successful performance of a TAP block
* any subject whose anatomy, or surgical procedure, in the opinion of the investigator, might preclude the potential successful performance of a TAP block

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents
Brief Summary: The primary purpose of this study is to compare the compliance rates of adolescents who take oral contraceptives (OCPs) continuously to those who take OCPs cyclically.


Options:
A: Inclusion Criteria:

* Female
* Age 15 to 18
* Presenting to the Gynecology and Adolescent Medicine Clinic for contraception

Exclusion Criteria:

* Prior use of the study medication with no improvement in symptoms
* Any medical condition that indicates continuous OCPs (i.e. acute menorrhagia, dysmenorrhea that did not previously respond to cyclical OCP use)
* Personal history of or current thromboembolic disorder
* First-degree relative(s) with thromboembolic disorder
* Cerebrovascular disease
* Coronary artery disease
* Cardiac valvular disease
* Hypertension (systolic blood pressure \> 160 mmHg or diastolic \> 100 mmHG)
* Diabetes with retinopathy/neuromyopathy/nephropathy)
* Breast cancer
* Endometrial cancer
* Undiagnosed abnormal uterine bleeding
* Cholestatic jaundice of pregnancy
* Hepatic tumor
* Known or suspected pregnancy
* Less than 6 months postpartum if breastfeeding
* Classic migraine with aura or any other neurological signs
* Gallbladder disease
* Taking any medications known to affect the efficacy of OCPs (i.e. phenytoin, phenobarbital, primidone, carbamazepine, griseofulvin, rifampin)
B: Inclusion Criteria:

* Obese adolescent (BMI \> 85th percentile for age)
* 9-19 years of age
* attending the ADOBE clinic at the University of Missouri

Exclusion Criteria:

* use of vit D supplements other than standard multi-vitamin preparation
* (i.e., should not be receiving vit D \> 1000 IU/d) use of medications that interfere with vit D metabolism (e.g., anti-convulsive)
* history of hepatic or renal disorders;
* undergoing ultraviolet radiation as medical therapy;
* pregnancy;
* cigarette smoking;
* current use of commercial tanning bed;
C: Inclusion Criteria:

* child aged between 12.0 and 17.0 years,
* child BMI =/\> 98th percentile,
* first language is English (or fluent in English)
* parent/s willing to participate in the programme with their child
* completion of written informed consent and/or assent prior to any study-specific procedures

Exclusion Criteria:

* severe intellectual difficulties,
* obesity secondary to genetic condition,
* limitations to engaging in physical activity
* use of medication known to effect body weight;
* limitations to using a smartphone device
* known family issues that would affect general compliance and attendance at follow-up visits.
D: Inclusion Criteria:

* Obese children and adolescents aged 10-18

Exclusion Criteria:

Children:

* Having associated learning difficulties
* Who have received medication for associated insulin resistance
* Refusal of parent/legal guardian to give informed consent.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy
Brief Summary: The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.


Options:
A: Inclusion Criteria:

* Diagnosis and clinical EEGrafica of refractory convulsive status epilepticus
* Refractoriness of the drug I and II line
* Written informed consent from parents or legal guardian.
* Administration of rating scales in the risk of mortality (PIM III) and severity of SE (stess, status epilepticusseverity score) to be performed prior to randomization.

Exclusion Criteria:

* contraindications to the use of the medication/s in the study.
* pregnant or suspected pregnant.
B: Inclusion Criteria:

* Children aged between 2 months and 12 years
* Presenting with generalised convulsions

Exclusion Criteria:

* Any child who had received an anticonvulsant agent within 1 hour of presentation
* Seizure stopped with rapid cooling or treatment of hypoglycaemia
* Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy
C: Inclusion Criteria:

* Paramedics or reliable witnesses verify 5 minutes of either continuous seizure activity or of repeated convulsive seizure activity where the patient does not regain consciousness (operationally defined as meaningful speech or obeying commands) between seizures.
* Patient is still seizing at the time of paramedic treatment with study medications.
* Estimated weight equal to or greater than 13 kg.
* Subject to be transported to a RAMPART participating hospital.

Exclusion Criteria:

* Major trauma as the precipitant of the seizure
* Hypoglycemia (as defined by local EMS protocol or a glucose \< 60 mg/dL)
* Known allergy to midazolam or lorazepam
* Cardiac arrest or heart rate (HR) \<40 beats per minute
* Sensitivity to benzodiazepines
* Medical alert tag marked with "RAMPART declined"
* Prior treatment of this seizure with diazepam autoinjector as part of another study
* Known pregnancy
* Prisoners
D: Inclusion Criteria:

* Children seventeen years and under will be identified through a Pediatric Neurology clinic at Primary Children's Medical Center,
* Known seizure disorder, AND
* Either have or will be prescribed a rescue anti-epileptic (rectal diazepam, or Diastat) for home use by their neurologist.

Exclusion Criteria:

* The neurologist does not prescribe a rescue medication for home use,
* 18 years of age or older,
* They have absence seizures, OR
* They have been prescribed lorazepam for home use for seizure activity.

Answer: D